| Source: |
| Type: |
| CardioProtective |
| 3712- | FA, | Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants |
| - | Review, | AD, | NA |
| 2846- | FIS, | Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity |
| - | in-vitro, | Nor, | NA |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2525- | H2, | Hydrogen-Rich Saline Attenuates Cardiac and Hepatic Injury in Doxorubicin Rat Model by Inhibiting Inflammation and Apoptosis |
| - | in-vivo, | NA, | NA |
| 2516- | H2, | Hydrogen Gas in Cancer Treatment |
| - | Review, | Var, | NA |
| 3770- | H2, | Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2901- | HNK, | doxoR, | Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts |
| - | in-vivo, | Nor, | NA |
| 2889- | HNK, | doxoR, | Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice |
| - | in-vivo, | Nor, | NA |
| 2893- | HNK, | doxoR, | Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts |
| - | in-vivo, | Nor, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2926- | LT, | Luteolin ameliorates rat myocardial ischemia-reperfusion injury through peroxiredoxin II activation: LUT's cardioprotection through PRX II |
| - | in-vitro, | Nor, | H9c2 |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3528- | Lyco, | The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3268- | Lyco, | Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders |
| - | Review, | AD, | NA |
| 3264- | Lyco, | Pharmacological potentials of lycopene against aging and aging‐related disorders: A review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3263- | Lyco, | Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening |
| - | in-vitro, | Nor, | H9c2 | - | in-vitro, | Stroke, | NA |
| 3261- | Lyco, | Lycopene and Vascular Health |
| - | Review, | Stroke, | NA |
| 3281- | Lyco, | Chemo, | Lycopene Supplementation for Patients Under Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| - | Review, | Var, | NA |
| 4784- | Lyco, | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives |
| - | Review, | Diabetic, | NA | - | Review, | CardioV, | NA |
| 4788- | Lyco, | Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review) |
| - | Review, | Var, | NA |
| 4801- | Lyco, | Lycopene in the Prevention of Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 4796- | Lyco, | The Anti-proliferation Effects of Lycopene on Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 4705- | MEL, | Melatonin: beyond circadian regulation - exploring its diverse physiological roles and therapeutic potential |
| - | Review, | Nor, | NA |
| 5785- | MET, | Metformin improves healthspan and lifespan in mice |
| - | in-vivo, | Nor, | NA |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
| 4112- | MF, | Novel protective effects of pulsed electromagnetic field ischemia/reperfusion injury rats |
| - | in-vivo, | Stroke, | NA |
| 3467- | MF, | Pulsed Magnetic Field Induces Angiogenesis and Improves Cardiac Function of Surgically Induced Infarcted Myocardium in Sprague-Dawley Rats |
| - | in-vivo, | Nor, | NA |
| 3482- | MF, | Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice |
| - | in-vitro, | NA, | NA |
| 3837- | Moringa, | Moringa oleifera: A Tree of Life as a Promising Medicinal Plant for Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 1798- | NarG, | Naringenin: A potential flavonoid phytochemical for cancer therapy |
| - | Review, | NA, | NA |
| 2042- | PB, | Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury |
| - | in-vitro, | Nor, | NA |
| 3252- | PBG, | Propolis Extract and Its Bioactive Compounds—From Traditional to Modern Extraction Technologies |
| - | Review, | NA, | NA |
| 5216- | PI, | doxoR, | Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 3587- | PI, | Piperine: A review of its biological effects |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 2948- | PL, | The promising potential of piperlongumine as an emerging therapeutics for cancer |
| - | Review, | Var, | NA |
| 4968- | PSO, | Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer |
| - | in-vitro, | Cerv, | NA |
| 3930- | PTS, | A Review of Pterostilbene Antioxidant Activity and Disease Modification |
| - | Review, | Var, | NA | - | Review, | adrenal, | NA | - | Review, | Stroke, | NA |
| 3924- | PTS, | Effect of resveratrol and pterostilbene on aging and longevity |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 98- | QC, | Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway |
| - | in-vivo, | Stroke, | NA |
| 5025- | QC, | New perspectives on the therapeutic potential of quercetin in non-communicable diseases: Targeting Nrf2 to counteract oxidative stress and inflammation |
| - | Review, | Nor, | NA |
| 3534- | QC, | Lyco, | Synergistic protection of quercetin and lycopene against oxidative stress via SIRT1-Nox4-ROS axis in HUVEC cells |
| - | in-vitro, | Nor, | HUVECs |
| 3601- | QC, | Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3354- | QC, | Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine |
| - | Review, | Var, | NA |
| 3353- | QC, | Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells |
| - | in-vitro, | Oral, | KON | - | in-vitro, | Nor, | MRC-5 |
| 3347- | QC, | Recent Advances in Potential Health Benefits of Quercetin |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1188 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid